Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
暂无分享,去创建一个
J. Crowley | B. Barlogie | G. Morgan | M. Dhodapkar | M. Zangari | J. Epstein | F. van Rhee | S. Yaccoby | A. Hoering | Y. Jethava | N. Petty | P. Qu | C. Heuck | R. Khan | C. Bailey | X. Papanikolaou | A. Rosenthal
[1] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[2] S. Mane,et al. Serial exome analysis of disease progression in premalignant gammopathies , 2014, Leukemia.
[3] Hui Li,et al. Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer , 2014, British Journal of Cancer.
[4] B. Barlogie,et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). , 2014, Blood.
[5] M. Kersten,et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial , 2014, Haematologica.
[6] T Hielscher,et al. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance , 2014, Leukemia.
[7] R. Fonseca,et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma , 2013, Leukemia.
[8] F. Prósper,et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.
[9] G. Mulligan,et al. A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma , 2013, PloS one.
[10] M. Dimopoulos,et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease , 2013, Leukemia.
[11] A. Dispenzieri,et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma , 2013, Leukemia.
[12] F. Zhan,et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.
[13] R. Braylan,et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study , 2013, Leukemia & lymphoma.
[14] A. Dispenzieri,et al. High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma , 2012, Leukemia.
[15] F. Zhan,et al. NEK 2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers , 2013 .
[16] P. Gobbi,et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study , 2011, Leukemia & lymphoma.
[17] Axel Benner,et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma , 2011, Haematologica.
[18] J. Sawyer. Metaphase cytogenetic techniques in multiple myeloma. , 2011, Methods in molecular biology.
[19] J. Blay,et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.
[20] R. Kyle,et al. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. , 2010, Mayo Clinic proceedings.
[21] F. Chan,et al. Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer , 2009, British Journal of Cancer.
[22] B. Barlogie,et al. The molecular characterization and clinical management of multiple myeloma in the post-genome era , 2009, Leukemia.
[23] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[24] R. Howard,et al. A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.
[25] Y. Yen,et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis , 2009, Molecular Cancer.
[26] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Therneau,et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.
[28] A. Órfão,et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.
[29] T. Therneau,et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.
[30] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[31] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[32] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[33] F. Zhan,et al. Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations , 2006, Leukemia.
[34] John O'Quigley,et al. Explained randomness in proportional hazards models , 2005, Statistics in medicine.
[35] E. Giné,et al. Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.
[36] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[38] John Crowley,et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.
[39] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[40] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[41] C. Winearls,et al. Acute myeloma kidney. , 1995, Kidney international.
[42] M. LeBlanc,et al. Survival Trees by Goodness of Split , 1993 .
[43] G. Tjønnfjord,et al. Incidence and follow‐up of asymptomatic multiple myeloma. , 1991, European journal of haematology.
[44] D.,et al. Regression Models and Life-Tables , 2022 .